Final overall survival results of a randomized trial comparing bortezomib plus pegylated liposomal doxorubicin with bortezomib alone in patients with relapsed or refractory multiple myeloma

Author:

Orlowski Robert Z.1,Nagler Arnon2,Sonneveld Pieter3,Bladé Joan4,Hajek Roman5,Spencer Andrew6,Robak Tadeusz7,Dmoszynska Anna8,Horvath Noemi9,Spicka Ivan10,Sutherland Heather J.11,Suvorov Alexander N.12,Xiu Liang13,Cakana Andrew13,Parekh Trilok13,San-Miguel Jesús F.14

Affiliation:

1. Department of Lymphoma/Myeloma, The University of Texas; MD Anderson Cancer Center; Houston Texas

2. Division of Hematology; Chaim Sheba Medical Center; Tel-Hashomer Israel

3. Department of Hematology; Erasmus Medical Center Cancer Institute; Rotterdam the Netherlands

4. Department of Clinical Hematology, August Pi I Sunyer Biomedical Research Institute; University of Barcelona; Barcelona Spain

5. Department of Hemato-Oncology, University Hospital and Faculty of Medicine; University of Ostrava; Ostrava Czech Republic

6. Malignant Hematology and Stem Cell Transplantation Service; The Alfred Hospital; Melbourne Australia

7. Department of Hematology; Medical University of Łódź; Łódź Poland

8. Hematology and Bone Marrow Transplant Department; Medical University of Lublin; Lublin Poland

9. Department of Hematology; Royal Adelaide Hospital; West Australia Australia

10. Department of Internal Medicine; Charles University General Faculty Hospital; Prague Czech Republic

11. Division of Hematology; University of British Columbia; Vancouver British Columbia Canada

12. Department of Hematology; First Republican Clinical Hospital of the Ministry of Healthcare of the Udmurt Republic; Izhevsk Russia

13. Janssen Research & Development, LLC; Raritan New Jersey

14. Center for Applied Medical Research, August Pi I Sunyer Biomedical Research Institute; University of Navarra; Pamplona Spain

Funder

Janssen Research & Development, LLC

Publisher

Wiley

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3